US Drug Recall Register

FDA Drug Recalls

14,450 recalls · Class II, newest first

Class II · Moderate risk Ongoing

Equate Stye Lubricant Eye Ointment

Reason Lack of Assurance of Sterility

Brassica Pharma Pvt Ltd NDC 79903-028-35 D-0352-2024
Class II · Moderate risk Ongoing

Equate Lubricant Eye Ointment

Reason Lack of Assurance of Sterility

Brassica Pharma Pvt Ltd NDC 79903-026-35 D-0351-2024
Class II · Moderate risk Terminated

Febuxostat Tablets

Reason CGMP Deviations

Amerisource Health Services LLC D-0314-2024
Class II · Moderate risk Ongoing

Norepinephrine Bitartrate in 5% Dextrose Injection

Reason Incorrect product concentration on the overwrap label: The overwrap label incorrectly identified the product strength as 4 mg / 250 mL; however, the primary bag label correctly identified the product strength as 8 mg / 250 mL.

Baxter Healthcare Corporation D-0336-2024
Class II · Moderate risk Terminated

Equate Cherry Cough Drops

Reason CGMP Deviations: Potential Glass and Silicone particulates in product

Bestco LLC D-0332-2024
Class II · Moderate risk Terminated

Kroger Cherry Cough Drops

Reason CGMP Deviations: Potential Glass and Silicone particulates in product

Bestco LLC D-0330-2024
Class II · Moderate risk Terminated

Meijer Cherry Cough Drops

Reason CGMP Deviations: Potential Glass and Silicone particulates in product

Bestco LLC D-0329-2024
Class II · Moderate risk Terminated

CVS Health Cherry Cough Drops

Reason CGMP Deviations: Potential Glass and Silicone particulates in product

Bestco LLC D-0328-2024
Class II · Moderate risk Terminated

Omeza Skin Protectant

Reason CGMP Deviations

Omeza LLC D-0289-2024
Class II · Moderate risk Completed

Fexofenadine Hydrochloride Tablets

Reason CGMP Deviations: Microbial contamination was reported in stagnant water in the duct of the manufacturing equipment.

Sun Pharmaceutical Industries INC NDC 51660-998-30 D-0273-2024
Class II · Moderate risk Completed

Zolpidem Tartrate Extended-Release Tablets

Reason CGMP Deviations: Microbial contamination was reported in stagnant water in the duct of the manufacturing equipment.

Sun Pharmaceutical Industries INC NDC 47335-308-88 D-0272-2024
Class II · Moderate risk Completed

Zolpidem Tartrate Extended-Release Tablets

Reason CGMP Deviations: Microbial contamination was reported in stagnant water in the duct of the manufacturing equipment.

Sun Pharmaceutical Industries INC NDC 47335-307-88 D-0271-2024
Class II · Moderate risk Completed

Niacin Extended-Release Tablets

Reason CGMP Deviations: Microbial contamination was reported in stagnant water in the duct of the manufacturing equipment.

Sun Pharmaceutical Industries INC NDC 47335-539-81 D-0270-2024
Class II · Moderate risk Completed

Niacin Extended-Release Tablets

Reason CGMP Deviations: Microbial contamination was reported in stagnant water in the duct of the manufacturing equipment.

Sun Pharmaceutical Industries INC NDC 47335-613-81 D-0269-2024
Class II · Moderate risk Completed

Mesalamine Delayed-Release Tablets

Reason CGMP Deviations: Microbial contamination was reported in stagnant water in the duct of the manufacturing equipment.

Sun Pharmaceutical Industries INC NDC 63304-175-13 D-0268-2024
Class II · Moderate risk Completed

Lurasidone Hydrochloride Tablets 120mg

Reason CGMP Deviations: Microbial contamination was reported in stagnant water in the duct of the manufacturing equipment.

Sun Pharmaceutical Industries INC NDC 47335-579-83 D-0267-2024
Class II · Moderate risk Completed

Lurasidone Hydrochloride Tablets 60mg

Reason CGMP Deviations: Microbial contamination was reported in stagnant water in the duct of the manufacturing equipment.

Sun Pharmaceutical Industries INC NDC 47335-639-83 D-0266-2024
Class II · Moderate risk Completed

Febuxostat Tablets 80 mg

Reason CGMP Deviations: Microbial contamination was reported in stagnant water in the duct of the manufacturing equipment.

Sun Pharmaceutical Industries INC NDC 47335-722-83 D-0265-2024
Class II · Moderate risk Completed

Febuxostat Tablets 40mg

Reason CGMP Deviations: Microbial contamination was reported in stagnant water in the duct of the manufacturing equipment.

Sun Pharmaceutical Industries INC NDC 47335-721-83 D-0264-2024
Class II · Moderate risk Completed

Cinacalcet Tablets 60mg

Reason CGMP Deviations: Microbial contamination was reported in stagnant water in the duct of the manufacturing equipment.

Sun Pharmaceutical Industries INC NDC 47335-380-83 D-0263-2024
Class II · Moderate risk Completed

Adrenalin

Reason Labeling: Incorrect or Missing Lot and/or Exp Date. The expiration date listed on the Repack Pouch Label is incorrect.

Henry Schein Inc. and Glove Club HSI Gloves Inc. NDC 42023-159-25 D-0342-2024